Wells Fargo Maintains Overweight on AbbVie, Raises Price Target to $295

Benzinga · 1d ago
Wells Fargo analyst Mohit Bansal maintains AbbVie (NYSE:ABBV) with a Overweight and raises the price target from $260 to $295.